A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
about
HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin.The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.PDGF upregulates CLEC-2 to induce T regulatory cellsGeneration of a monoclonal antibody recognizing the CEACAM glycan structure and inhibiting adhesion using cancer tissue-originated spheroid as an antigen.Establishment and characterization of a penile cancer cell line, penl1, with a deleterious TP53 mutation as a paradigm of HPV-negative penile carcinogenesis.Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.Platelet-activating factor podoplanin: from discovery to drug developmentAntibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.Podoplanin Expression in Canine Melanoma.The multifaceted role of podoplanin expression in hepatocellular carcinoma.Evaluation of Podoplanin in Oral Leukoplakia and Oral Squamous Cell Carcinoma.Development of RAP Tag, a Novel Tagging System for Protein Detection and Purification.Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer.Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis.C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets.A Real-Time Near-Infrared Fluorescence Imaging Method for the Detection of Oral Cancers in Mice Using an Indocyanine Green-Labeled Podoplanin Antibody.Expression and Dynamics of Podoplanin in Cultured Osteoblasts with Mechanostress and Mineralization Stimulus.LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer.Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.MicroRNA-21 in cancer-associated fibroblasts supports lung adenocarcinoma progression.Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog PodoplaninIdentification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1
P2860
Q30843463-8E028BBD-3AEA-49FE-8436-B414DCE7730EQ35975006-C62EB0B3-00F0-4ECC-BC3A-CD8F8B8CD4E5Q36546538-502D9768-6238-4157-93DB-5A489AC43255Q36557110-F5DDABB8-202B-4CDD-83E2-156C23681B7EQ36819894-1B3E7882-41A4-4083-AFC2-F21C2E5CC707Q37588351-8B23380F-6228-4224-88B0-33CBD1AB01ABQ37648097-5D09198D-8FC6-46E6-90EE-4344B1C1985BQ38260977-2835AFCC-A59E-4C50-9E05-FF358CB0E24EQ38325438-D3B76262-5082-4BD2-8FAD-FFC86CAEC90CQ38663138-B56DA02F-F573-4E23-B639-9D2CD5D7803BQ38892678-64310F14-9619-46FA-8ACF-950CA196A856Q38905443-E502B506-6DD5-4AEE-AD02-9BFABD160834Q40546654-6D5EC2C3-1827-4173-B88E-516BBFC767DBQ41866316-7AA5DF40-F320-49D9-80B2-35C59A50ADB8Q41908609-5E2FA9B7-AF41-41F0-9286-ED2B36F910F9Q42290572-CB11B282-15E8-42D2-A54B-2B177C2863D6Q42292310-18F057C5-03F9-4DA8-8EC7-AAE4FAC70C45Q47161245-220B2EF8-CE96-4F8D-9EC4-767900B0C489Q48367537-931C7E47-F43E-4D47-BABF-1C8917D066DDQ50351148-8A5ABD97-7FA1-43F3-AF77-05FBF4239FF4Q52591453-E1722787-BA6B-4BD8-9A5E-8DB0B8BD5D40Q55096315-E51C4D4D-A522-44E3-96CD-79846491CCBCQ55100500-EE617A1C-1397-48CD-AB24-74DA0EED4E23Q55249763-D229C51F-F055-4C81-8856-AD2CA99D5A03Q55363949-7864459D-9BC3-42EA-90B7-C3EE71A1DA67Q58568945-62F24ADD-BA21-43DD-B80C-58842D54F57AQ58700578-EE96583C-4479-46CB-9131-95B018DAAAAB
P2860
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
@ast
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
@en
type
label
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
@ast
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
@en
prefLabel
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
@ast
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
@en
P2860
P356
P1433
P1476
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
@en
P2093
Mika Kato Kaneko
P2860
P2888
P356
10.1038/SREP05924
P407
P577
2014-08-01T00:00:00Z
P5875
P6179
1036511816